Plasma acylation stimulating protein concentration and subcutaneous adipose tissue C3 mRNA expression in nondiabetic and type 2 diabetic men.
We studied the effect of an oral fat load on plasma acylation stimulating protein (ASP) concentrations in 9 lean healthy (age 59+/-2 years, body mass index [BMI] 23.2+/-0.4 kg/m(2); both mean+/-SEM), 9 obese nondiabetic (58+/-2 years, BMI 29.4+/-0.5 kg/m(2)), and 12 type 2 diabetic (60+/-2 years, BMI 29.6+/-1.0 kg/m(2)) men. Because ASP is a cleavage product of complement protein C3 (C3adesArg) and its secretion is regulated by insulin, we also examined the subcutaneous adipose tissue expression of C3 mRNA before and after a 240-minute euglycemic hyperinsulinemic clamp in a subgroup of these men. Plasma ASP concentration and adipose tissue C3 mRNA expression were higher in the obese groups than in the lean men. Plasma ASP concentration did not change significantly after the fat load. Fasting plasma ASP concentration and C3 mRNA expression were correlated negatively with insulin sensitivity and positively with the magnitude of postprandial lipemia in nondiabetic but not in type 2 diabetic men. The expression of C3 mRNA was not regulated by insulin. These data suggest that ASP is associated with whole-body glucose and lipid metabolism in nondiabetic individuals, whereas metabolic disturbances in diabetes may overcome the regulatory role of ASP in lipid and glucose metabolism.
Koistinen
H A
HA
Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland. heikki_koistinen@yahoo.com
Vidal
H
H
Karonen
S L
SL
Dusserre
E
E
Vallier
P
P
Koivisto
V A
VA
Ebeling
P
P
D000273:Adipose Tissue / Q000378:metabolism*; D001798:Blood Proteins / Q000378:metabolism*; D003176:Complement C3 / Q000096:biosynthesis / Q000235:genetics*; D015926:Complement C3a / Q000031:analogs & derivatives*; D003920:Diabetes Mellitus / Q000235:genetics / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000235:genetics / Q000378:metabolism*; D005215:Fasting; D005223:Fats / Q000008:administration & dosage; D006801:Humans; D006949:Hyperlipidemias / Q000209:etiology / Q000378:metabolism; D007333:Insulin Resistance; D008297:Male; D008875:Middle Aged; D009765:Obesity; D019518:Postprandial Period; D012333:RNA, Messenger / Q000096:biosynthesis; D014280:Triglycerides / Q000097:blood
D001798:Blood Proteins; D003176:Complement C3; D005223:Fats; D012333:RNA, Messenger; D014280:Triglycerides; C044541:complement C3a, des-Arg-(77)-; D015926:Complement C3a